The Phase III trial conducted in nonsquamous NSCLC treated with nivolumab was in favor of a predictive value [6], while in the phase III trial in squamous NSCLC the expression of PD-L1 did not correlate with patients’ outcomes [5]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.